Emergent BioSolutions (EBS) Osake Kurssi

Emergent BioSolutions Inc is primarily active in the biopharmaceutical industry.

Emergent BioSolutions Inc faces competition from several players in the market. Some of the main competitors of Emergent BioSolutions Inc include companies like Pfizer Inc, GlaxoSmithKline plc, Sanofi SA, and Johnson & Johnson. These companies are also involved in the biopharmaceutical sector and operate in similar areas such as vaccine development, contract manufacturing, and biodefense solutions. However, Emergent BioSolutions Inc has positioned itself as a leader in the industry, particularly due to its expertise in biodefense solutions and its strong portfolio of products and services.

Emergent BioSolutions Inc is a renowned pharmaceutical company with a rich history and background. Established in 1998, Emergent is dedicated to developing innovative solutions to address public health threats. Over the years, the company has built a strong reputation for its expertise in biodefense, vaccines, therapeutics, and contract manufacturing services. Emergent BioSolutions has played a crucial role in supplying vaccines and treatments for various diseases, including anthrax, smallpox, and COVID-19. With a commitment to protecting and enhancing global health, Emergent continues to be at the forefront of life-saving medical advancements.

Emergent BioSolutions Inc, a leading biopharmaceutical company, has achieved significant milestones in its journey. Notably, the company received a U.S. FDA licensure for its proprietary BioThrax® vaccine against anthrax, establishing itself as the sole provider of such a critical defense product for the U.S. government. Additionally, Emergent successfully developed and commercialized various medical countermeasures, including Vaccinia Immune Globulin Intravenous (VIGIV) for smallpox treatment and Trobigard® auto-injector for atropine/pralidoxime chloride poisoning. Furthermore, the company obtained FDA approval for its first-in-class narcolepsy therapy, NARCAN® nasal spray. These achievements highlight Emergent BioSolutions Inc's commitment to enhancing public health through innovative solutions and its contributions to epidemic and pandemic preparedness.

Emergent BioSolutions Inc primarily operates in the United States. As a global specialty biopharmaceutical company, the company's headquarters are located in Gaithersburg, Maryland. With a strong presence in the United States, Emergent BioSolutions Inc focuses on developing and manufacturing therapies for public health threats. The company's products are used in various countries and regions worldwide, supporting preparedness and response efforts for biodefense, emerging infectious diseases, and other public health emergencies.

Emergent BioSolutions Inc represents values of integrity, innovation, and dedication to public health. Following their corporate philosophy, they strive to deliver high-quality products and solutions for public health threats. The company focuses on developing, manufacturing, and delivering medical countermeasures for biodefense and emerging infectious diseases. By collaborating with governments, healthcare organizations, and stakeholders worldwide, Emergent BioSolutions Inc aims to protect and enhance the well-being of individuals and communities. With a commitment to scientific expertise and a patient-centered approach, they contribute to the preparedness and response efforts in the face of various health challenges.

Analyytikot asettavat tällä hetkellä Emergent BioSolutions-osakkeelle keskimääräisen tavoitehinnan 10,00 USD (mediaani: 10,00 USD), mikä merkitsee +46,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 7 analyytikkoarvioon.

Emergent BioSolutions Analyytikkojen kursstavoitteet 2026

7 analyytikkoa arvioi tällä hetkellä Emergent BioSolutions-osaketta: 5 suosittaa ostoa, 1 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Emergent BioSolutions-yhtiöltä 657,02 M USD liikevaihtoa ja 0,36 USD osakekohtaista tulosta.

Emergent BioSolutions Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Emergent BioSolutions-osake noteerataan hintaan 6,09 EUR (6,83 USD).

Emergent BioSolutions-osake (EBS) on listattuna 7 pörssissä, muun muassa: NYSE (EBS), London (0IGA.L), SIX (Zürich) (ER4.SW), Frankfurt (ER4.F), München (ER4.MU), Düsseldorf (ER4.DU).

Emergent BioSolutions Inc. is a US biotechnology company based in Gaithersburg, Maryland. They specialize in the development and manufacturing of biological products, including vaccines and antibodies, to combat infectious diseases, as well as medications and products for emergency situations. The company is divided into three business segments: BioDefense, Civilian Emergency Medicine, and Emergent Family of Companies. Each segment focuses on a specific market and has its own products. The BioDefense segment develops and produces vaccines and antibodies used to combat bioterrorist threats such as anthrax, smallpox, and botulism. This includes the BioThrax vaccine, the only FDA-approved anthrax vaccine in the US, as well as anthrax countermeasures such as Anthrasil. In Civilian Emergency Medicine, Emergent offers products for the treatment of acute medical emergencies, including medical devices and diagnostic equipment for rapid testing. In this segment, Emergent also has several partnerships with government agencies and health organizations to provide products needed in natural disasters and other emergencies. The Emergent Family of Companies includes Emergent's acquisitions and partnerships in other areas and niches of biotechnology, including medical device manufacturing and the development of therapies for various indications such as cancer, autoimmune diseases, and infectious diseases. An important focus of Emergent is collaboration with government agencies and international partners. The company has a specialized team that works with various government organizations and institutions in the US and around the world. This gives Emergent access to specialized resources and enables them to develop and produce products that meet the requirements of the respective government agencies and organizations. As a company with a strong focus on research and development, Emergent invests significant amounts in expanding its product pipeline. Future products include vaccines and therapies for HIV, Ebola, and Zika. Emergent primarily markets its products to government agencies and health organizations. However, the company also benefits from the increasing demand for products to combat infectious diseases due to natural disasters or bioterrorist attacks. Overall, Emergent BioSolutions is a key player in the medical and biotech industry, especially in terms of the development and production of biologics. The company's threefold division allows it to operate in various biotechnology niches and constantly expand its product pipeline. Collaboration with government agencies and the ability to quickly respond to changing requirements are crucial factors for the success of Emergent BioSolutions.

odotettu liikevaihto Emergent BioSolutions on 657,02 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Emergent BioSolutions on 19,06 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Emergent BioSolutions:n hinta-voitto-suhde (P/E) on tällä hetkellä 18,78. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Emergent BioSolutions-osakkeen arvostusta.

Emergent BioSolutions:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,54. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Emergent BioSolutions-osakkeen arvostuskennuslukuna.

Emergent BioSolutions:n Eulpool-laatuscore on 3/10.

Emergent BioSolutions:n ISIN on US29089Q1058. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Emergent BioSolutions:n WKN on A0LC2W. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Emergent BioSolutions:n ticker on EBS. Tämä pörssinoteeraus käytetään Emergent BioSolutions-osakkeiden kauppaan pörssissä.